drugset / Trial / NCT04371796
Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
Phase 2
Unknown
20 enrolled
Sichuan Cancer Hospital and Research Institute
Innovent Biologics, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study was to investigate the safety and efficacy of Sintilimab (IBI308) in patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy in patients with stage II-IIIA NSCLC
Timeline
- Start
- 2020-05-10
- Primary completion
- 2021-06-30
- Completion
- 2021-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |